Introduction
Cyclic nucleotide signaling in lymphoid cells is regulated by a diverse set of phosphodiesterase (PDE) families and selective inhibitors of these PDEs have proven to be both of therapeutic interest and of use in the analysis of lymphoid signal transduction pathways. At a minimum, lymphoid cells express PDE1B, PDE3B, PDE4A, B and D, and PDE7A, all enzymes that can catabolize 3':5' cyclic adenosine monophosphate (cAMP) 1 2 3 4 5 . In studies of the mature B cell malignancy B-CLL, we and others have found that both non-specific PDE inhibitors such as theophylline and the PDE4-specific inhibitor rolipram induce apoptosis in leukemic cells over a 48 to 72 hour period 6 7 8 . While rolipram also induces apoptosis in peripheral B cells, albeit superimposed on a high normal basal apoptotic rate, the same agent has little or no apoptotic effect on peripheral T cells 8 .
PDE4 inhibitors induce a mitochondrial apoptotic pathway in B-
CLL cells with release of cytochrome c, caspase 9 and 3 activation, and PARP cleavage. This pathway may be triggered by PDE4 inhibitor-induced up-regulation of serine/threonine phosphatase PP2A activity, with resultant dephosphorylation of the pro-apoptotic BH3-only Bcl2 family member BAD, release of BAD from the cytosolic adapter protein 14-3-3, and translocation of BAD to mitochondria 9 . In contrast, although PDE3B is expressed in B-CLL, when used alone, PDE3 inhibitors do not induce apoptosis in B-CLL 10 . PDE7A is expressed and regulated in B-CLL cells, but reagents that allow selective inhibition of this PDE over the 48 to 72 hours required for apoptosis studies have not yet become available 11 .
While most studies of cAMP signaling in lymphoid cells have focused on protein kinase A (PKA), recently a novel family of cAMP effector proteins, EPAC1 and EPAC2 (also known as cAMP-GEFI/II) has been identified in other cell lineages 12, 13 14 . Upon binding cAMP, EPAC catalyzes release of GDP from the Ras family GTPases Rap1 and Rap2, allowing the more abundant intracellular GTP to bind and convert the GTPase to an active, signaling conformation 12 . In an effort to develop a reagent that would allow selective analysis of EPAC-induced signaling, Bos and colleagues subsequently identified a cAMP analogue, 8-(4-chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate (8CPT-2Me-cAMP), that activates EPAC while having little or no activity on PKA 15 . While prior studies implicated Rap1 in a lineage-dependent manner in either cAMP-induced activation or inhibition of extracellular signal-regulated kinase (ERK), experiments utilizing 8CPT-2Me-cAMP failed to support a role for EPAC or Rap1 in regulating the ERK pathway 16 15,17 . In contrast, studies with 8CPT-2Me-cAMP support a role for Rap1 (and EPAC) in augmenting cellular adhesion to extracellular matrix and to other cells through integrin "inside-out" signaling 18 .
Here, we have examined the hypothesis that EPAC is responsible for the particular sensitivity of 
Materials and methods

Reagents
The following reagents were obtained from commercial sources: 8-Br-cAMP, N6-benzoyl- 
Patient selection
After IRB-approved informed consent, blood was drawn in heparinized tubes from patients with flow cytometry-verified B-CLL, CD3+CD4+ T-CLL or leukemic phase mantle cell lymphoma who were either untreated or at least one month post-chemotherapy. Patients with active infections or other serious medical conditions were not included in this study. 
Cell purification and culture
Rap1 GTPase activation assay
The level of activated Rap1 was determined by "pulldown" analysis. The technique for the pulldown analysis has been previously described 20 . Ten million cells were harvested in lysis buffer (50mM TrisCl, pH 7.2, 200mM NaCl, 5mM MgCl 2 , 1% NP40, 10% glycerol, 2 µg/mL antipain, aprotinin, chemostatin, leupeptin and pepstatin, 1 mM PMSF). Whole cell lysate was incubated for two hours with 6µl of glutathione sepharose 4B beads preassociated with 6µg
GST-RalGDS. The beads were washed three times with cell lysis buffer and GTP bound GTPase was released from the beads by addition of 1X protein sample buffer and boiling for 5 minutes.
The released GTPases were then detected by Western blot analysis using an anti-Rap1 antibody and ECL Plus chemiluminescence (Amersham, Piscataway, NJ).
Western analysis
Antibodies reactive with CREB and phospho-CREB (Ser133) were from Cell Signaling.
Results
EPAC1 transcript in B lineage but not T lineage mature lymphoid cells
To contrast EPAC1 expression in B-CLL cells with that of other cell lineages, we performed RT PCR on RNA purified from a variety of leukemic or normal circulating hematopoietic cell populations. EPAC1 transcript was readily detectable in CD5+ CD19+ B-CLL cells obtained from three different patients (Fig. 1A ) . The PCR product from B-CLL cell cDNA was verified as being derived from EPAC1 transcript by cloning and sequencing. EPAC1
transcript was also detected in purified CD19+ peripheral B cells from normal donors, but was undetectable in cDNA from purified normal peripheral T cells, monocytes or neutrophils ( 
PDE4 inhibitors activate Rap1 in B-CLL but not other hematopoietic cells
To determine whether cAMP signaling activates Rap1 in primary B-CLL cells, we performed a Rap1 "pulldown" assay in which GST-RalGDS chimeric protein is used to isolate GTP-bound Rap1 from cell lysates. Treatment of leukemic cells from two B-CLL patients with the PDE4 inhibitor rolipram (10 µM) and the adenylate cyclase activator forskolin (40 µM) for five minutes induced robust Rap1 activation in primary B-CLL cells ( Fig. 2A) . In contrast, consistent with the EPAC1 transcript results described above, rolipram/forskolin treatment of leukemic cells from a patient with CD3+CD4+ T-CLL did not lead to Rap1 activation. Phorbol esters such as phorbol myristate acetate (PMA) have been reported to induce Rap1 activation in a variety of cell lineages including B lymphocytes, perhaps as a result of activation of Rap1 GDP exchange factors such as CalDAG-GEF1 that contain both DAG-and Ca 2+ -binding domains 21 22 .
As a control, we found that treatment for five minutes with 300 nM PMA activated Rap1 in both B and T-CLL samples ( Fig. 2A) . phosphorylation while forskolin alone had no effect (Fig 4A) . PMA (300 nM) and the non- previously shown to be biologically active in B lineage cells 10, 11 . Treatment of leukemic cells with either of these inhibitors failed to induce Rap1 activation (Fig. 4C) . Thus, PDE4 enzymes appear to play a unique role in the regulation of EPAC and Rap1 activation in B-CLL cells.
To contrast the time course of PDE4 inhibitor-mediated activation of PKA and EPAC in B-CLL cells with that of 8-CPT-2Me-cAMP-mediated activation of EPAC, we incubated B-CLL cells for varying lengths of time with either 10 µM rolipram or 50 µM 8-CPT-2Me-cAMP, followed by Rap1 and CREB analysis. Both rolipram (Fig. 4D ) and 8-CPT-2Me-cAMP (Fig. 4E) induced detectable Rap1 activation in B-CLL cells within 15 minutes, further increased at one hour, and remained elevated for at least eight hours. CREB Ser 133 phosphorylation was detected at all time points following rolipram but not 8-CPT-2Me treatment, although a low level of CREB phosphorylation was detectable at the one hour time point in 8-CPT-2Me-treated cells ( Fig. 4D and E) . 
Selective activation of EPAC reduces basal apoptosis in B-CLL
Discussion
In this study, we demonstrate the functional expression of EPAC in B-CLL cells, but not in T-CLL, peripheral B or T cells, monocytes or neutrophils. Further, we find that the selective activation of EPAC is anti-apoptotic while inhibition of PKA activity with [R p ]-8Br-cAMPS substantially reduces rolipram-mediated apoptosis. We hypothesize that PDE4 inhibitors simultaneously induce pro-and anti-apoptotic signals through PKA and EPAC, respectively, and that the PKA-mediated pro-apoptotic pathway suppresses the anti-apoptotic signal ordinarily transmitted by EPAC activation.
In keeping with the expression of EPAC transcript in B-CLL cells, we find that rolipram, a prototypic PDE4 inhibitor, and 8CPT-2Me-cAMP, a specific EPAC agonist, activate Rap1 in these leukemic cells but not in the other cell populations studied. These findings suggest that agents that activate cAMP-mediated signaling will uniquely activate Rap1 signaling pathways in 89's pro-apoptotic activity is likely to be unrelated to its ability to inhibit PKA in CLL cells [31] [32] [33] .
Further studies with agents that selectively inhibit PKA signaling will be required for unequivocal confirmation that PDE4 inhibitor-induced apoptosis is PKA-mediated. 
Figure Legends
